Cancer Medicines Outcomes Programme Public Health Scotland (CMOP-PHS) report for the Scottish Medicines Consortium (SMC)
Bispecific antibody treatment of adults with relapsed and refractory multiple myeloma: SMC2863

About this release

This release by Public Health Scotland (PHS) uses information from the National SACT dataset.

This work was requested by the Scottish Medicines Consortium (SMC) to support their decision-making processes. Talquetamab as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and an anti-CD38 antibody and have demonstrated disease progression on the last therapy is being assessed for use by NHS Scotland (SMC2863).

The aim of this work was to capture real-world evidence from Scotland on the use of bispecific antibodies for treatment of adults with relapsed and refractory multiple myeloma. Details of the presumptions made to identify this cohort are described in Section 2.3.1. of the main report. This work will enable SMC members to assess the relevance of information, provided as part of the assessment process for SMC2863, to patients in Scotland.

The objectives of this work were to:

• Determine the number of patients prescribed a bispecific antibody for the treatment of relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an IMiD, a PI, and an anti-CD38 antibody.
• Describe the baseline characteristics of patients prescribed a bispecific antibody for the treatment of relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an IMiD, a PI, and an anti-CD38 antibody.